Prognostic Factors and Staging in Multiple Myeloma

Rafael Fonseca, Jesus San Miguel

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

The field of multiple myeloma prognostication is replete with studies that have shown the value of independent predictors in determining clinical outcome. It is clear that host factors and factors intrinsic to the cells are the ultimate determinants of prognosis. In the immediate period after diagnosis, those factors related to the host are likely to be more relevant, whereas with passing time factors intrinsic to the cells predominate. At a minimum, we recommend that a comprehensive molecular cytogenetic assessment be performed at diagnosis, together with conventional evaluation, including β2-microglobulin and albumin. In addition, information on proliferative activity of plasma cells may be of value. The introduction of novel methods of prognostication should be strongly considered in all clinical trials.

Original languageEnglish (US)
Pages (from-to)1115-1140
Number of pages26
JournalHematology/Oncology Clinics of North America
Volume21
Issue number6
DOIs
StatePublished - Dec 2007

Fingerprint

Multiple Myeloma
Intrinsic Factor
Plasma Cells
Cytogenetics
Albumins
Clinical Trials

ASJC Scopus subject areas

  • Oncology
  • Hematology

Cite this

Prognostic Factors and Staging in Multiple Myeloma. / Fonseca, Rafael; San Miguel, Jesus.

In: Hematology/Oncology Clinics of North America, Vol. 21, No. 6, 12.2007, p. 1115-1140.

Research output: Contribution to journalArticle

@article{bbeaa2804c9944a2a20f006ccb4111ea,
title = "Prognostic Factors and Staging in Multiple Myeloma",
abstract = "The field of multiple myeloma prognostication is replete with studies that have shown the value of independent predictors in determining clinical outcome. It is clear that host factors and factors intrinsic to the cells are the ultimate determinants of prognosis. In the immediate period after diagnosis, those factors related to the host are likely to be more relevant, whereas with passing time factors intrinsic to the cells predominate. At a minimum, we recommend that a comprehensive molecular cytogenetic assessment be performed at diagnosis, together with conventional evaluation, including β2-microglobulin and albumin. In addition, information on proliferative activity of plasma cells may be of value. The introduction of novel methods of prognostication should be strongly considered in all clinical trials.",
author = "Rafael Fonseca and {San Miguel}, Jesus",
year = "2007",
month = "12",
doi = "10.1016/j.hoc.2007.08.010",
language = "English (US)",
volume = "21",
pages = "1115--1140",
journal = "Hematology/Oncology Clinics of North America",
issn = "0889-8588",
publisher = "W.B. Saunders Ltd",
number = "6",

}

TY - JOUR

T1 - Prognostic Factors and Staging in Multiple Myeloma

AU - Fonseca, Rafael

AU - San Miguel, Jesus

PY - 2007/12

Y1 - 2007/12

N2 - The field of multiple myeloma prognostication is replete with studies that have shown the value of independent predictors in determining clinical outcome. It is clear that host factors and factors intrinsic to the cells are the ultimate determinants of prognosis. In the immediate period after diagnosis, those factors related to the host are likely to be more relevant, whereas with passing time factors intrinsic to the cells predominate. At a minimum, we recommend that a comprehensive molecular cytogenetic assessment be performed at diagnosis, together with conventional evaluation, including β2-microglobulin and albumin. In addition, information on proliferative activity of plasma cells may be of value. The introduction of novel methods of prognostication should be strongly considered in all clinical trials.

AB - The field of multiple myeloma prognostication is replete with studies that have shown the value of independent predictors in determining clinical outcome. It is clear that host factors and factors intrinsic to the cells are the ultimate determinants of prognosis. In the immediate period after diagnosis, those factors related to the host are likely to be more relevant, whereas with passing time factors intrinsic to the cells predominate. At a minimum, we recommend that a comprehensive molecular cytogenetic assessment be performed at diagnosis, together with conventional evaluation, including β2-microglobulin and albumin. In addition, information on proliferative activity of plasma cells may be of value. The introduction of novel methods of prognostication should be strongly considered in all clinical trials.

UR - http://www.scopus.com/inward/record.url?scp=35948990849&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=35948990849&partnerID=8YFLogxK

U2 - 10.1016/j.hoc.2007.08.010

DO - 10.1016/j.hoc.2007.08.010

M3 - Article

C2 - 17996591

AN - SCOPUS:35948990849

VL - 21

SP - 1115

EP - 1140

JO - Hematology/Oncology Clinics of North America

JF - Hematology/Oncology Clinics of North America

SN - 0889-8588

IS - 6

ER -